HR Execs on the Move

Mixhers

www.mixhers.com

 
Mixhers is a company that provides supplements designed specifically for womens health and wellness, with each product carefully crafted to support women in all stages of life.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Amanda Rasmussen
Director of Supply Chain and Logistics Profile
Britnee Nuehring
Chief Sales Marketing Officer Profile

Similar Companies

Novasite Pharmaceutical

Novasite Pharmaceutical is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Terumo Aortic

Aortic solutions that address every segment of the aorta. #borntostandout

Lupin

Lupin is a USD 2.55 billion innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Innodia

Innodia Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.